Results 1 to 10 of about 6,345 (201)

Prevalence and Predictors of Substance Use Disorder Due to Gabapentinoids in Patients With Chronic Non‐Cancer Pain: A Cross‐Sectional Study [PDF]

Health Science Reports
Background and Aims The increase in the use of gabapentinoids in the treatment of patients with chronic non‐cancer pain (CNCP) has drawn attention to the possibility of substance use disorder (SUD) due to gabapentinoids.
Neele Kufeld, Klaus Weckbecker, Eva Münster, Norbert Scherbaum, Michael Specka, Johannes Just   +5 more
doaj   +3 more sources

Characterization of hospitalized patients who received naloxone while receiving opioids with or without gabapentinoids [PDF]

Mental Health Clinician, 2021
Introduction: Gabapentin and pregabalin (gabapentinoids) can be given with opioids for opioid-sparing and adjuvant analgesic effects. In the context of certain comorbidities and high dosages, coadministration of these agents can lead to respiratory ...
Payal H. Desai, PharmD, BCCCP, Olesya Taylor, PharmD, BCPS, Kunal J. Shah, PharmD, Kirk E. Evoy, PharmD, BCACP, BC-ADM, CTTS, Alyssa M. Peckham, PharmD, BCPP   +4 more
doaj   +3 more sources

Opioids and Gabapentinoids Utilisation and Their Related-Mortality Trends in the United Kingdom Primary Care Setting, 2010–2019: A Cross-National, Population-Based Comparison Study

Frontiers in Pharmacology, 2021
Background: There is growing concern over the increasing utilisation trends of opioids and gabapentinoids across but there is lack of data assessing and comparing the utilisation trends across the four United Kingdom countries.
Amanj Kurdi
exaly   +3 more sources

Possible Signals of Ocular Disorders Associated with Gabapentinoids: A Three-Arm Study [PDF]

Pharmaceuticals
Background: Gabapentinoids (gabapentin and pregabalin) are medications used to treat epilepsy and diabetic neuropathy. Reports of gabapentinoid-associated adverse drug reactions (ADRs) are increasing.
Mya Murray, Amira Guirguis, Paul Deslandes, John Martin Corkery, Stefania Chiappini, Mariacristina Parravano, Fabrizio Schifano   +6 more
doaj   +2 more sources

Trends in Co-Prescribing Opioids and Gabapentinoids Among Medicare Beneficiaries, 2017 to 2022 [PDF]

Medical Sciences
Background: Co-prescribing opioids and gabapentinoids (GABA, gabapentin and pregabalin) is associated with increased risk of falls, fractures, opioid overdose and deaths.
Mukaila Raji, Aashnika Sujit, Jordan Westra, Shilpa Rajagopal, Yong-Fang Kuo   +4 more
doaj   +2 more sources

Effectiveness of Gabapentinoids in Neuropathic Pain: A Single-Center Retrospective Study at a Specialized Institution in Mexico [PDF]

Pharmacy
Background/Objectives: Gabapentinoids are first-line treatments for neuropathic pain (NP); however, real-world evidence regarding their safety and effectiveness in complex clinical populations remains limited.
Carlos Eduardo Estrada-De La Rosa, Felipe Alexis Avalos-Salgado, Nancy Evelyn Navarro-Ruiz, Erika Fabiola López-Villalobos, Roberto de Jesús Sandoval-Muñiz, Monserratt Abud-González, María Luisa Muñoz-Almaguer, Raymundo Escutia-Gutiérrez   +7 more
doaj   +2 more sources

Lack of impact of OCTN1 gene polymorphisms on clinical outcomes of gabapentinoids in Pakistani patients with neuropathic pain.

PLoS ONE, 2022
Background and objectiveGabapentinoids are the first-line drugs for neuropathic pain. These drugs are the substrate of organic cation transporter (OCTN1) for renal excretion and absorption across the intestinal epithelium.
Abida Shaheen, Syed Mahboob Alam, Fahad Azam, Salman Ahmad Saleem, Moosa Khan, Syed Saud Hasan, Afrose Liaquat   +6 more
doaj   +2 more sources

Opioid and gabapentinoid prescriptions in England from 2015 to 2020.

PLoS ONE, 2022
PurposeConcerns gradually arose about misuse of gabapentinoids (gabapentin and pregabalin), especially when used in combination with opioids. Because it can be a driver of usage, trends in prescribing habits may be interesting to analyse. The aim of this
Yixue Xia, Patrice Forget
doaj   +2 more sources

Efficacy and safety of pregabalin and gabapentin in spinal stenosis: a systematic review and meta-analysis

Frontiers in Pharmacology, 2023
Background and Objective: Multimodal management of spinal stenosis is on the rise, and central sensitisation inhibitors are playing an essential role in the treatment of central sensitisation processes.
Telmo Martínez, Gonzalo Mariscal, Jose Enrique de la Rubia Ortí, Carlos Barrios   +3 more
doaj   +1 more source

Novel Drug Targets and Emerging Pharmacotherapies in Neuropathic Pain

Pharmaceutics, 2023
Neuropathic pain is a debilitating condition characterized by abnormal signaling within the nervous system, resulting in persistent and often intense sensations of pain.
Jurga Bernatoniene, Arunas Sciupokas, Dalia Marija Kopustinskiene, Kestutis Petrikonis   +3 more
doaj   +1 more source